About 14.5 million people in the United States had cancer as of 2014. That number is unfortunately expected to rise to 19 million in 2024. Many researchers are investigating cures for cancer and one of the leading ones is Dr. Clay Siegall of Seattle Genetics. He like the other researchers are hoping that their efforts lead to a decline in cancer. The old way of treating cancer was chemotherapy, radiation, and the like which sometimes works and sometimes doesn’t. It also has terrible side effects. Dr. Clay Siegall says that the wave of the future in treating cancer is instead targeted cancer therapies as well and genetic sequencing.
Being diagnosed with cancer is all too common. Almost 40% of people will at some point be diagnosed with some form of it. For this reason there is a great deal of scientific research into why it occurs and how to cure it. Scientists are now looking at cancer on the genetic level and are finding that it is small errors in the genetic code of patient’s that is to blame. Before long having your genetic code sequenced will be as common as having your blood drawn. Each person has over 20,000 genes and a small error in just one of these can have an outsized effect.
Dr. Clay Siegall got his Ph.D. in genetics. For several years he worked for the National Cancer Institute after graduating. He then got a job at Bristol-Meyers Squibb in the private sector. He started Seattle Genetics in 1998 so that he could better carry out his research. His company has one cancer drug on the market and several others that are in different phases of development.
As a leader in the industry. Dr. Clay Siegall has also joined the board of other companies that are researching cures for cancer. This includes Alder Biopharmaceuticals, Inc., Ultragenyx Pharmaceutical, and Mirna Therapeutics, Inc. He has also produced over 70 publications on cancer and he has 15 patents approved by the United States Patent Office.